Arvinas, Inc. (NASDAQ:ARVN) Stock Position Cut by NEOS Investment Management LLC

NEOS Investment Management LLC trimmed its stake in shares of Arvinas, Inc. (NASDAQ:ARVN) by 29.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,835 shares of the company’s stock after selling 4,915 shares during the quarter. NEOS Investment Management LLC’s holdings in Arvinas were worth $227,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ARVN. Rhumbline Advisers raised its holdings in Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after purchasing an additional 754 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Arvinas by 0.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock valued at $2,694,000 after purchasing an additional 777 shares during the period. KBC Group NV lifted its holdings in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock valued at $279,000 after buying an additional 1,367 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Arvinas by 12.5% during the fourth quarter. LPL Financial LLC now owns 18,669 shares of the company’s stock worth $358,000 after acquiring an additional 2,077 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Stock Performance

Arvinas stock opened at $7.02 on Tuesday. Arvinas, Inc. has a twelve month low of $6.88 and a twelve month high of $41.34. The firm has a market cap of $482.78 million, a PE ratio of -2.53 and a beta of 1.95. The firm’s 50 day moving average price is $15.05 and its two-hundred day moving average price is $20.51.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the business earned ($2.53) earnings per share. Equities analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ARVN. Bank of America reduced their price objective on shares of Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. The Goldman Sachs Group lowered shares of Arvinas from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $70.00 to $15.00 in a research report on Thursday, March 13th. Wedbush downgraded Arvinas from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $57.00 to $12.00 in a research report on Wednesday, March 12th. BTIG Research started coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price on the stock. Finally, Barclays decreased their price target on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.50.

Insider Transactions at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Noah Berkowitz sold 8,658 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the sale, the insider now owns 110,023 shares of the company’s stock, valued at $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 in the last three months. Corporate insiders own 5.23% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.